ProfoundBio nabs $55M to advance ADC portfolio

By The Science Advisory Board staff writers

July 12, 2021 -- Oncology biotherapeutics company ProfoundBio has secured $55 million in funding that it plans to use to further develop its antibody-drug conjugate (ADC) portfolio, which includes a number of solid tumor-targeting candidates.

The series A funding round was led by Lilly Asia Venture and co-led by Lyfe Capital, with support from Sequoia Capital China and Oriza, according to the firm. ProfoundBio has offices in Seattle and Suzhou, China.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.